These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Atypical onset of bicalutamide-induced liver injury. Yun GY; Kim SH; Kim SW; Joo JS; Kim JS; Lee ES; Lee BS; Kang SH; Moon HS; Sung JK; Lee HY; Kim KH World J Gastroenterol; 2016 Apr; 22(15):4062-5. PubMed ID: 27099451 [TBL] [Abstract][Full Text] [Related]
4. [DRUG-INDUCED INTERSTITIAL LUNG DISEASE DURING COMBINED ANDROGEN BLOCKADE WITH BICALUTAMIDE AND LEUPRORELIN ACETATE FOR PROSTATE CANCER]. Maeda K; Osafune T; Masuda Y; Takeda T; Kageyama S; Narita M; Kawauchi A Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):36-40. PubMed ID: 31956217 [TBL] [Abstract][Full Text] [Related]
5. Images in clinical medicine. Gynecomastia induced by prostate-cancer treatment. Michalopoulos NV; Keshtgar MR N Engl J Med; 2012 Oct; 367(15):1449. PubMed ID: 23050528 [No Abstract] [Full Text] [Related]
6. Photosensitive drug eruption induced by bicalutamide within the UVB action spectrum. Sasada K; Sakabe J; Tamura A; Kasuya A; Shimauchi T; Ito T; Hirakawa S; Tokura Y Eur J Dermatol; 2012; 22(3):402-3. PubMed ID: 22503957 [No Abstract] [Full Text] [Related]
7. [Management of gynecomastia induced by bicalutamide]. Haddad E Ann Urol (Paris); 2006 Dec; 40 Suppl 2():S49-52. PubMed ID: 17361921 [TBL] [Abstract][Full Text] [Related]
8. Prostate cancer tissue is masked by bicalutamide: a case report. Ellinger J; Bastian PJ; Biermann K; Schmidt ME; Textor J; Bollmann D; Zhou H; Müller SC Eur J Med Res; 2007 May; 12(5):212-5. PubMed ID: 17513193 [TBL] [Abstract][Full Text] [Related]
9. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer. Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426 [TBL] [Abstract][Full Text] [Related]
10. Bicalutamide causes heart failure in an elderly patient with prostate cancer. Guirguis K Expert Opin Drug Saf; 2016; 15(3):297-302. PubMed ID: 26745594 [TBL] [Abstract][Full Text] [Related]
11. Depression related to (neo)adjuvant hormonal therapy for prostate cancer. van Tol-Geerdink JJ; Leer JW; van Lin EN; Schimmel EC; Stalmeier PF Radiother Oncol; 2011 Feb; 98(2):203-6. PubMed ID: 21256610 [TBL] [Abstract][Full Text] [Related]
12. Interstitial pneumonitis induced by bicalutamide given for prostate cancer. Masago T; Watanabe T; Nemoto R; Motoda K Int J Clin Oncol; 2011 Dec; 16(6):763-5. PubMed ID: 21537882 [TBL] [Abstract][Full Text] [Related]
13. [Gynecomastia as a complication of hormonotherapy for prostate cancer: effect of prophylactic breast irradiation]. Abdah-Bortnyak R; Bernstein Z; Ramon N; Zalman D; Shnaider J; Kuten A Harefuah; 2007 Feb; 146(2):126-8, 164-5. PubMed ID: 17352282 [TBL] [Abstract][Full Text] [Related]
14. Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Van Poppel H Eur Urol; 2007 Jul; 52(1):115. PubMed ID: 17270341 [No Abstract] [Full Text] [Related]
15. Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer: Relating 33 Years of Patient Clinical Care. Strum SB; Scholz MC JAMA Oncol; 2016 May; 2(5):686. PubMed ID: 27244678 [No Abstract] [Full Text] [Related]
17. Escitalopram in treatment of antiandrogen-related mood disturbance in a patient with chronic schizophrenia and adenocarcinoma of the prostate. Kao LC; Chen LF; Hsu YC; Chuang WC; Chao HL; Chang HA; Kao YC; Chen TY; Tzeng NS Gen Hosp Psychiatry; 2015; 37(4):e11-2. PubMed ID: 25911327 [No Abstract] [Full Text] [Related]
18. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. Iversen P; McLeod DG; See WA; Morris T; Armstrong J; Wirth MP; BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214 [TBL] [Abstract][Full Text] [Related]
20. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. Wadhwa VK; Weston R; Mistry R; Parr NJ BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]